** Shares of Orthocell OCC.AX rise 8.1% to A$1.27, snap a four-day losing streak
** Stock set for its strongest session since April 10, if gains hold
** The biotech firm announces appointment of its first four U.S. distributors of its flagship nerve repair product Remplir
** Co says it is targeting to appoint about 10 U.S. distributors by June-end which would account for representation in around 25 states in the U.S.
** Stock down 7% YTD, including moves in current session
(Reporting by Jasmeen Ara Shaikh in Bengaluru)
((JasmeenAraIslam.Shaikh@thomsonreuters.com;))
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。